Exact Sciences raises $120M to get its cancer test on the market

A week after swaying an FDA panel with its colorectal cancer screen, Exact Sciences ($EXAS) raised $119.7 million through a stock offering, flipping 10 million shares at $12.75 each. With the proceeds, the company plans to pay Cologuard's way through FDA approval, eventually launching the stool-based cancer diagnostic. Release

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.